Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-United: daplusiran/tomligisiran followed by bepirovirsen in chronic hepatitis B on nucleos(t)ide analogue background therapy
CTR20244953Phase 2Active
- Sponsor
- GSK
- Start
- Feb 2025
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tomligisiran and bepirovirsen in Chronic Hepatitis B (CHB) (4 arms), sponsored by GSK. Started Feb 2025; status: active.
02
Drugs
tomligisiranbepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20244953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244953.